Idiopathic inflammatory myositis (IIM) is classified into 4 subtypes based on clinical and histopathological features. Polymyositis and dermatomyositis (PM/DM) are 2 of those subtypes in addition to immune-mediated necrotizing myopathy and inclusion body myositis. The presence of autoantibodies and inflammatory infiltration in the muscles suggests that idiopathic inflammatory myositis is an autoimmune condition, but the target autoantigens have not yet been identified. Apart from symmetric proximal muscle weakness, polymyositis and dermatomyositis have several clinical manifestations in common when compared to inclusion body myositis and necrotizing myopathy and can be grouped for discussion.
The most commonly used criteria for PM/DM are Peter/Bohan Criteria.
Inflammatory myopathies are immune-mediated processes triggered by environmental factors in genetically susceptible people.
The estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 persons, and incidence is approximately 1.2 to 19 million persons at risk per year. The incidence of myositis is increasing over time due to an increase in detection rate. Dermatomyositis is bimodal in age distribution with one peak at 5 to 15 years and another at 45 to 60 years. Polymyositis rarely occurs in the pediatric age group, and the mean age is between 50 to 60 years. The overall female-to-male incidence ratio is 2 to 3:1. In the United States, the African American to Caucasian ratio of incidence is 3 to 4:1. In Europe, the prevalence significantly increases from the north to south, and this may be due to either environmental or genetic reasons.
The following are the proposed pathogenetic mechanisms:
The characteristic histopathologic features of polymyositis and dermatomyositis (PM/DM) are the presence of mononuclear inflammatory cell infiltrates and degeneration and regeneration of muscle fibers. Atrophy of muscle fibers in a perifascicular fashion is the hallmark feature of dermatomyositis.
Immunopathology: Endomysial inflammatory cell infiltrates mainly composed of CD8+T cells, and in addition, CD4+T cells, macrophages, and dendritic cells are seen in polymyositis. Perivascular and perimysial infiltration of CD4+T cells, macrophages, dendritic cells, and B cells are seen in dermatomyositis. The difference in immunohistopathologic features of these 2 subsets of myositis suggests that different pathogenic mechanisms could be involved in them, with T-cell-mediated muscle damage in PM and a role for microvessels in DM.
Increased expression of MHC class I and II molecules are present both on regenerating fibers and normal appearing muscle fibers in patients with myositis. The MHC Class I antigen expression is more frequently observed that MHC Class II and the mechanism by which the MHC expression in muscle is induced has not been elucidated.
The hallmark clinical feature of IIM is symmetric proximal muscle weakness and is manifested as difficulty in getting up from sitting position, climbing stairs, lifting heavy objects, and overhead abduction of the arm.In addition to muscle weakness, dermatomyositis (DM) patients often present with a characteristic skin rash. Gottron papule and heliotrope rash are the pathognomonic skin finding of DM.
Description of the major skin findings in DM is given below:
These lesions (except holster sign) are photosensitive and may be aggravated by ultraviolet radiation. Other manifestations include dystrophic cuticles; peri-ungual erythema; abnormal nail bed capillary loops; diffuse flat erythema over the forehead, chin, and knees; photosensitivity; shawl sign; V-sign; panniculitis; and calcinosis cutis.
Dermatomyositis includes several clinically distinct phenotypes, and specific autoantibodies are associated with each unique phenotype.
Patients with dermatomyositis have little or no muscle involvement and are referred to as hypomyopathic or amyopathic dermatomyositis.
Extramuscular manifestations of IIM include arthritis, Raynaud phenomenon, dysphagia, and interstitial lung disease.
When a patient's history and proximal weakness are compatible, they should initially be evaluated by measuring the muscle enzymes including creatine phosphokinase (CPK), Aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH), and aldolase. CPK level usually correlates with the severity of muscle inflammation but, rarely, can be normal. Serial muscle enzyme measurements are useful in following myositis activity and are used to supplement serial strength testing. Inflammatory markers like ESR and CRP can also be elevated. Autoantibodies, muscle imaging, electrophysiologic examination, and muscle biopsy can be used to confirm the diagnosis. Autoantibodies are present in more than 80% of patients with inflammatory myositis. They are classified as (1) myositis-specific antibodies and (2) myositis-associated antibodies.
If the muscle enzymes are abnormal, an objective evaluation of muscle inflammation is performed with EMG or MRI to document muscle abnormality and to identify a site for biopsy.
Abnormal findings expected in EMG are low amplitude, short duration, and polyphasic potential; increased membrane irritability; spontaneous fibrillations; and early recruitment. EMG should be done only on one side to reserve the contralateral side for the muscle biopsy to avoid electrical burn artifact. MRI using short tau inversion recovery (STIR) sequence detects focal inflammation as bright signals, and a T1 sequence is useful in detecting atrophy and scarring.
Muscle biopsy is helpful in differentiating polymyositis and dermatomyositis (PM/DM) based on their distinct histopathological features. In patients with DM, a skin biopsy will show mild atrophy of the epidermis with vascular changes in the basal layer and perivascular inflammatory infiltrates in the dermis.
Chest X-ray should be done in all patients with PM or DM to detect lung involvement such as interstitial lung disease. Pulmonary function test and CT chest can be done based on the patient's symptoms and in cases of abnormal chest X-ray. An increased prevalence of malignancy is described in patients with inflammatory myositis, particularly dermatomyositis. Hence, age-appropriate screening with colonoscopy, low dose CT chest, Pap smear, and mammogram in addition to the routine blood count, chemistries, and urinalysis must be done in these patients. Patients with dermatomyositis who have positive anti-NXP2 or anti-TIF 1 antibody are at increased risk of cancer within 3 years of their diagnosis; therefore, PET/CT scans should also be considered.
Corticosteroids are the initial therapy and cornerstone in the management of both polymyositis and dermatomyositis (PM/DM). The common practice is to start with prednisone 1 to 2 mg/kg/day. In patients with severe weakness and those with extramuscular involvement, intravenous methylprednisolone 1mg/day for 3 consecutive days may be used. Patients should be closely followed, and a steroid dose can be slowly tapered based on the clinical response. There is no guideline available for initial dosing or tapering of steroids, so the treatment should be under an experienced physician and based on clinical judgment. Patient and family should be educated about the disease and the treatment. Patients should be monitored for steroid-related adverse effects, particularly osteoporosis, steroid-induced myopathy, hypertension, hyperglycemia, and weight gain.
Steroid-sparing therapy like methotrexate and azathioprine (in patients with normal thiopurine methyltransferase (TPMT) activity) can be used in patients who develop adverse effects to steroids or those having trouble with tapering the steroids. They are also used in patients with inadequate response to steroids. Methotrexate is effective in treating the muscle and joint symptoms but should be used with caution in patients with lung involvement because of its potential lung toxicity. Calcineurin inhibitors (cyclosporine and tacrolimus) are effective in treating skin manifestations and, along with mycophenolate mofetil, are recommended for the treatment of interstitial lung disease. Cyclophosphamide can be used in severe and rapidly progressive interstitial lung disease. Treatment with cyclophosphamide carries the risk of infertility. Intravenous immunoglobulins (IVIG) also has been shown to be beneficial in the treatment of dermatomyositis.
Rituximab, anti-CD 20 monoclonal antibody is effective in treating myositis and myositis-related interstitial lung disease. Rituximab is preferred over cyclophosphamide by many clinicians due to its better tolerance and adverse effect profile. Although some patients might respond to anti-TNF agents, the studies on etanercept and infliximab have shown conflicting results. Few cases report tocilizumab (anti-IL-6 antibody), anakinra (anti-IL 1 antibody), alemtuzumab (anti-CD-52), tofacitinib, and ruxolitinib (JAK-inhibitors) as effective agents in treating autoimmune myositis. However, there are no confirmatory studies, and these drugs are used only in resistant cases.
Tailored physical exercise programs and rehabilitation under a physiatrist or physical therapist is shown to improve the muscle strength and decrease the disability even in patients with acute inflammatory myopathy. Supportive treatment for PM/DM includes sunlight avoidance, use of sunscreens in DM, and aspiration precautions in patients with oro-pharyngeal myopathy.
The differential diagnosis of polymyositis and dermatomyositis (PM/DM) includes:
The management of polymyositis and dermatomyositis is with a multidisciplinary team because of the complexity of treatment. While the initial treatment is usually done by the rheumatologist, the patient followup is by the priimary care provider and nurse practitioner. Corticosteroids are the initial therapy and cornerstone in the management of both polymyositis and dermatomyositis (PM/DM). There is no guideline available for initial dosing or tapering of steroids, so the treatment should be under an experienced physician and based on clinical judgment. Patient and family should be educated about the disease and the treatment. Patients should be monitored for steroid-related adverse effects, particularly osteoporosis, steroid-induced myopathy, hypertension, hyperglycemia, and weight gain.
Steroid-sparing therapy like methotrexate and azathioprine (in patients with normal thiopurine methyltransferase (TPMT) activity) can be used in patients who develop adverse effects to steroids or those having trouble with tapering the steroids. They are also used in patients with inadequate response to steroids. Side effects of these disease-modifying drugs need to be monitored.
Rituximab, anti-CD 20 monoclonal antibody is effective in treating myositis and myositis-related interstitial lung disease. Rituximab is preferred over cyclophosphamide by many clinicians due to its better tolerance and adverse effect profile.
Finally, tailored physical exercise programs and rehabilitation under a physiatrist or physical therapist is shown to improve the muscle strength and decrease the disability even in patients with acute inflammatory myopathy. Supportive treatment for PM/DM includes sunlight avoidance, use of sunscreens in DM, and aspiration precautions in patients with oro-pharyngeal myopathy. The outlook for patients with polymyositis and dermatomyositis is guarded. (level V)
|||Bohan A,Peter JB, Polymyositis and dermatomyositis (first of two parts). The New England journal of medicine. 1975 Feb 13 [PubMed PMID: 1090839]|
|||Ghirardello A,Borella E,Beggio M,Franceschini F,Fredi M,Doria A, Myositis autoantibodies and clinical phenotypes. Auto- immunity highlights. 2014 Dec [PubMed PMID: 26000158]|
|||Cox NH,Lawrence CM,Langtry JA,Ive FA, Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Archives of dermatology. 1990 Jan [PubMed PMID: 2297252]|
|||Pipitone N,Salvarani C, Treatment of inflammatory myopathies. Expert review of clinical immunology. 2018 Jul [PubMed PMID: 29952659]|
|||Dalakas MC, Inflammatory Muscle Diseases. The New England journal of medicine. 2015 Jul 23 [PubMed PMID: 26200989]|
|||McGrath ER,Doughty CT,Amato AA, Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018 Oct; [PubMed PMID: 30341597]|